Floatz logo

ly3321367

Cutaneous Melanoma

Eli Lilly and CompanyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

152 Active assets in the Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB

View all 50 →

Same molecule, other indications

ly3321367 is also rated in:

Microsatellite Instability-High (MSI-H) Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →